ViiV’s four-monthly HIV drug maintains viral suppression at 12 months
ViiV Healthcare’s investigational four-monthly HIV drug maintains viral suppression at 12 months in a Phase IIb trial. In the EMBRACE trial …
Post
-
-
Suvoda unveils split budget feature for clinical trial site management
Suvoda has introduced new split budget functionality to its clinical trial software, Budgeting & Benchmarking, supporting sponsors and contract research …
-
Mahzi doses first patient in MZ-1866 trial for Pitt Hopkins syndrome
Mahzi Therapeutics has dosed the first patient in its Phase I/II UNITE study assessing MZ-1866, an investigational gene therapy targeting …
-
DOR/ISL Phase III data underlines trend for shift towards two-drug STRs in HIV
A 96-week Phase III study in adults with HIV who were previously virologically suppressed on oral antiretroviral therapy (ART) has …
-
EU clinical trial target could bring in additional €4bn funding
A further €4bn ($4.72bn) a year in funding could come into Europe if targets to increase clinical trials in the …
-
FDA reversal on mRNA-1010 could transform the seasonal influenza vaccines market
Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010. This announcement comes …
-
Enhancing clinical trials in obesity by integrating clinical outcome assessments (COAs) and digital health technologies (DHTs)
As obesity reaches epidemic proportions worldwide, clinical trial teams face mounting pressure to demonstrate meaningful health benefits beyond weight loss …
-
Jaguar Gene Therapy completes Cohort I patient dosing in JAG201 clinical trial
Clinical-stage biotechnology company Jaguar Gene Therapy has completed dosing in Cohort I of its first-in-human clinical trial investigating JAG201 for …
-
Novo Nordisk-partnered drug shows 19.7% weight loss in Phase II trial
Novo Nordisk and United Laboratories’ jointly developed triple G drug has achieved a 19.7% weight loss in a Phase II …
-
Vico Therapeutics initiates patient dosing for VO659 Phase I/IIa trial
Vico Therapeutics has started patient dosing in an expanded cohort under a twice-yearly regimen for its Phase I/IIa clinical trial …
-
HIV patients show lower steatotic liver disease with ViiV’s Dovato vs Biktarvy
Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to Biktarvy. In the …
-
Gene editing takes centre stage in FDA’s new rare disease approval pathway
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway”, a new …
-
C4 Therapeutics doses first patient in MOMENTUM trial for multiple myeloma
C4 Therapeutics has dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, an oral ikaros family zinc …
-
Gossamer Bio reports topline Phase III PROSERA outcomes for PAH
Gossamer Bio has reported topline data from the Phase III PROSERA study evaluating seralutinib in patients with pulmonary arterial hypertension …
-
Novo Nordisk’s CagriSema bested by Lilly’s Zepbound in head-to-head trial
Novo Nordisk’s CagriSema has been outperformed by Eli Lilly’s Zepbound (tirzepatide) in a head-to-head obesity trial. The Phase III REDEFINE 4 …
